GRAL 11-DAY DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now . The upcoming lead plaintiff deadline is August 4, 2026 .

The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate a statistically significant reduction in late-stage (Stage III and IV) cancer diagnoses.

The action centers on whether GRAIL selectively promoted favorable top-line results from initial screening rounds while withholding granular data and ignoring internal indicators suggesting that a three-year timeline would be insufficient to achieve the trial’s primary endpoint.

The artificial inflation came to an abrupt end on February 19, 2026 , when GRAIL announced top-line results from its NHS-Galleri trial. The disclosures shocked the market: Primary Endpoint Not Met: GRAIL revealed that the trial failed to meet its primary endpoint of a statistically significant reduction in late-stage cancers. Admission of Flawed Timeline: The company admitted that it "probably should have allowed for a longer follow-up period."

Market Reaction: Following these disclosures, GRAL shares collapsed by 50.55% in a single trading session—plummeting from a close of $101.53 to $50.21 per share on February 20, 2026, and erasing over $2.2 billion in market capitalization.

“We’re focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration,” said Reed Kathrein , the Hagens Berman partner leading the firm’s investigation of the pending claims in the filed lawsuit.

If purchased or acquired GRAIL common stock between May 13, 2025, and February 19, 2026 , and suffered significant losses, you have until August 4, 2026 , to ask the court to appoint you as lead plaintiff.